Salvage Ovarian FANG™ Vaccine + Bevacizumab

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.

Patients will receive 1.0 x 10e7 cells via intradermal injection one day each cycle for a maximum of 12 doses as long as sufficient material is available and subject is clinically stable. Additionally, patients will receive bevacizumab 10 mg/kg intravenously (prior to Vigil™ administration) every 2 weeks (4 weeks=1 cycle).

Biological: Vigil™ Vaccine

Patients meeting eligibility criteria will receive Autologous Vigil™ vaccine will be supplied by Gradalis,Inc. Patients will receive 1.0 x 10e7 cells via intradermal injection one day each cycle for a maximum of 12 doses as long as sufficient material is available and subject is clinically stable. Additionally, patients will receive bevacizumab 10 mg/kg intravenously (prior to Vigil™ administration) every 2 weeks (4 weeks=1 cycle).

Time to progression (TTP) following bevacizumab integrated with Vigil vaccine in patients failing standard of care in study CL-PTL 105 or in those not otherwise qualifying after vaccine production. This will be measured from the treatment start date (date of first dose) to either the date the patient is first recorded as having disease recurrence (even if the patient went off treatment because of toxicity), or the date of death if the patient dies due to any causes before progression.

Response Rate [ Time Frame: Up to 12 months ]

Response will be evaluated using the revised Response Evaluation Criteria in Solid Tumors (RECIST) guideline.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Recurrent cisplatinum resistant/refractory disease (defined as the appearance of any measurable or evaluable lesion or as asymptomatic CA-125 levels greater than 100 u/mL at two consecutive measurements with no intervening therapy.

Successful manufacturing of 4 vials of Vigil™ vaccine.

Recovered from all clinically relevant toxicities related to prior therapies.

ECOG PS 0-2 prior to Vigil™ vaccine administration.

Normal organ and marrow function as defined below:

Absolute granulocyte count ≥1,500/mm3

Absolute lymphocyte count ≥ 200/mm3

Platelets ≥100,000/mm3

Total bilirubin ≤1.5 x ULN

AST(SGOT)/ALT(SGPT)/alkaline phosphatase ≤2.5 x ULN

Creatinine <1.5 mg/dL

INR < 1.5

Baseline blood pressure must be under 140/90

Urine protein-to-creatinine ratio < 1.0 mg/dL.

Patients must be off all "statin" drugs for ≥ 2 weeks prior to initiation of therapy.

Ability to understand and the willingness to sign a written informed protocol specific consent.